FT Markets Data
HealthStream Inc

HealthStream Announces Third Quarter 2024 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Oct. 21, 2024-- HealthStream, Inc. (the “Company”) (Nasdaq: HSTM), a leading healthcare technology platform for workforce solutions, announced today results for the third quarter ended September 30, 2024.

Third Quarter 2024

  • Revenues of $73.1 million in the third quarter of 2024, up 3.9% from $70.3 million in the third quarter of 2023
  • Operating income of $6.5 million in the third quarter of 2024, up 33.6% from $4.9 million in the third quarter of 2023
  • Net income of $5.7 million in the third quarter of 2024, up 48.0% from $3.9 million in the third quarter of 2023
  • Earnings per share (EPS) of $0.19 per share (diluted) in the third quarter of 2024, up from $0.13 per share (diluted) in the third quarter of 2023
  • Adjusted EBITDA1 of $17.7 million in the third quarter of 2024, up 9.0% from $16.2 million in the third quarter of 2023
  • Board of Directors declared a quarterly cash dividend of $0.028 per share, payable on November 15, 2024, to holders of record on November 4, 2024

1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release.

Financial Results:

Third Quarter 2024 Compared to Third Quarter 2023

Revenues for the third quarter of 2024 increased by $2.8 million, or 3.9%, to $73.1 million, compared to $70.3 million for the third quarter of 2023. Subscription revenues increased by $2.5 million, or 3.6%, and professional services revenues increased by $0.3 million, or 10.8%, compared to the third quarter of 2023.

Operating income was $6.5 million for the third quarter of 2024, up 33.6% from $4.9 million in the third quarter of 2023. The improvement in operating income was primarily attributable to increased revenues and an increase in capitalized labor associated with software development activities, partially offset by increases in labor costs.

Net income was $5.7 million in the third quarter of 2024, up 48.0% from $3.9 million in the third quarter of 2023, and EPS was $0.19 per share (diluted) in the third quarter of 2024, up from $0.13 per share (diluted) in the third quarter of 2023.

Adjusted EBITDA was $17.7 million for the third quarter of 2024, up 9.0% from $16.2 million in the third quarter of 2023.

At September 30, 2024, the Company had cash and cash equivalents and marketable securities of $94.9 million. The Company does not have any outstanding indebtedness for borrowed money. Capital expenditures incurred during the third quarter of 2024 were $6.9 million.

Year-to-Date 2024 Compared to Year-to-Date 2023

For the nine months ended September 30, 2024, revenues were $217.4 million, an increase of 4.3% over revenues of $208.5 million for the first nine months of 2023. Operating income for the first nine months of 2024 increased by 41.1% to $16.6 million, compared to $11.8 million for the first nine months of 2023. The increase in operating income was primarily attributable to higher revenues and an increase in capitalized labor associated with software development activities. Operating income was also impacted by higher expenses, including software, bad debt related to a customer bankruptcy during the second quarter of 2024, cloud hosting, labor costs, amortization, general marketing, and travel expenses. Net income for the first nine months of 2024 increased to $15.1 million, compared to $10.6 million for the first nine months of 2023. Earnings per share were $0.50 per share (diluted) for the first nine months of 2024, compared to $0.35 per share (diluted) for the first nine months of 2023. Adjusted EBITDA increased by 11.7% to $50.6 million for the first nine months of 2024, compared to $45.3 million for the first nine months of 2023.

Other Business Updates

On October 21, 2024, the Board approved a quarterly cash dividend under the Company's dividend policy of $0.028 per share, payable on November 15, 2024, to holders of record on November 4, 2024.

Financial Outlook for 2024

The Company is updating its guidance for 2024 for certain of the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2024, see the table included on page nine of this release.

 

 

Full Year 2024 Guidance

 

 

 

Low

 

 

 

 

High

 

 

Revenue

 

$

290.0

 

-

 

$

292.0

 

million2

 

 

 

 

 

 

 

 

 

 

 

Net Income

 

$

18.5

 

-

 

$

19.5

 

million3

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA1

 

$

66.0

 

-

 

$

67.5

 

million4

 

 

 

 

 

 

 

 

 

 

 

Capital Expenditures

 

$

28.0

 

-

 

$

30.0

 

million

1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release.

2 Previous expected Revenue guidance range was $292.0 to $296.0 million.

3 Previous expected Net Income guidance range was $16.7 to $18.6 million.

4 Previous expected Adjusted EBITDA guidance range was $64.5 to $67.5 million.

The Company’s guidance for 2024 as set forth above reflects the Company’s assumptions regarding, among other things, expectations for new sales and renewals, and assumes that general economic conditions, including inflationary pressures, do not deteriorate. This consolidated guidance does not include the impact of any acquisitions that we may complete during 2024, gains or losses from changes in the fair value of minority investments, or impairment of long-lived assets.

Commenting on third quarter 2024 results, Robert A. Frist, Jr., Chief Executive Officer, HealthStream, said, “Our quarterly financial performance showed year-over-year increases in each of the major categories we highlight in our earnings release, which included record quarterly revenues and record adjusted EBITDA. We continue to see competitive benefits emerge from our innovative platform strategy, which we believe is paving the way for increased, long-term value for our customers and shareholders.”

A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Communications, will be held on Tuesday, October 22, 2024, at 9:00 a.m. (ET). Participants may access the conference call live via webcast using this link: https://edge.media-server.com/mmc/p/xb3ciqdq. To participate via telephone, please register in advance using this link: https://register.vevent.com/register/BIfd60adeb38ad4c6488f94e1c8216c837. A replay of the conference call and webcast will be archived on the Company’s website in the Investor Relations section under “Events & Presentations.”

Use of Non-GAAP Financial Measures

This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company’s financial results and ongoing operational performance. In order to better assess the Company’s financial results, management believes that net income before interest, income taxes, stock-based compensation, depreciation and amortization, and changes in fair value of, including gains (losses) on the sale of, non-marketable equity investments (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. In addition, as discussed below, for periods ended on or prior to December 31, 2023, adjusted EBITDA excludes the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. We believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. In addition, certain short-term cash incentive bonuses and performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.

As previously disclosed, prior to the Company early adopting ASU 2021-08 effective January 1, 2022, following the completion of any acquisition by the Company, the Company was required to record the acquired deferred revenue at fair value as defined in GAAP, which typically resulted in a write-down of the acquired deferred revenue. In connection therewith, management determined that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred revenue write-downs associated with fair value accounting for businesses acquired prior to the January 1, 2022 effective date of the Company's adoption of ASU 2021-08 (the “Pre-2022 Acquisitions”) provided useful information to investors because the deferred revenue write-down recognized in periods after any such Pre-2022 Acquisitions could, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance. Following the adoption of ASU 2021-08, contracts acquired in an acquisition completed on or after January 1, 2022 have been measured as if the Company had originated the contract (rather than the contract being measured at fair value) such that, for such acquisitions, the Company no longer records deferred revenue write-downs associated with acquired businesses. With respect to periods ended on or prior to December 31, 2023, the Company has included an adjustment in the calculation of adjusted EBITDA for the impact of deferred revenue write-downs associated with the Pre-2022 Acquisitions consistent with this prior accounting standard, given the ongoing impact of such deferred revenue on our financial results under GAAP over this time period. With respect to periods beginning on and after January 1, 2024, the Company no longer recognizes any deferred revenue write-downs associated with the Pre-2022 Acquisitions under GAAP, and accordingly such deferred revenue write-downs are not an adjustment in connection with the calculation of adjusted EBITDA for periods on and after January 1, 2024.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.

This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.

About HealthStream

HealthStream (Nasdaq: HSTM) is the healthcare industry’s largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information about HealthStream, visit www.healthstream.com or call 800-521-0574.

 

HEALTHSTREAM, INC.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30, 2024

 

 

September 30, 2023

 

 

September 30, 2024

 

 

September 30, 2023

 

Revenues, net

 

$

73,095

 

 

$

70,339

 

 

$

217,411

 

 

$

208,482

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues (excluding depreciation and amortization)

 

 

24,470

 

 

 

23,587

 

 

 

72,825

 

 

 

71,010

 

Product development

 

 

12,100

 

 

 

10,901

 

 

 

36,208

 

 

 

33,610

 

Sales and marketing

 

 

11,497

 

 

 

11,290

 

 

 

34,676

 

 

 

34,324

 

Other general and administrative expenses

 

 

8,457

 

 

 

9,295

 

 

 

26,325

 

 

 

27,223

 

Depreciation and amortization

 

 

10,073

 

 

 

10,403

 

 

 

30,779

 

 

 

30,550

 

Total operating costs and expenses

 

 

66,597

 

 

 

65,476

 

 

 

200,813

 

 

 

196,717

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

6,498

 

 

 

4,863

 

 

 

16,598

 

 

 

11,765

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income, net

 

 

981

 

 

 

590

 

 

 

2,722

 

 

 

1,329

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax provision

 

 

7,479

 

 

 

5,453

 

 

 

19,320

 

 

 

13,094

 

Income tax provision

 

 

1,754

 

 

 

1,586

 

 

 

4,202

 

 

 

2,471

 

Net income

 

$

5,725

 

 

$

3,867

 

 

$

15,118

 

 

$

10,623

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.19

 

 

$

0.13

 

 

$

0.50

 

 

$

0.35

 

Diluted

 

$

0.19

 

 

$

0.13

 

 

$

0.50

 

 

$

0.35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares of common stock outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

30,409

 

 

 

30,683

 

 

 

30,374

 

 

 

30,653

 

Diluted

 

 

30,590

 

 

 

30,769

 

 

 

30,512

 

 

 

30,734

 

Dividends declared per share

 

$

0.028

 

 

$

0.025

 

 

$

0.084

 

 

$

0.075

 

 

HEALTHSTREAM, INC.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2024

 

 

2023

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

57,489

 

 

$

40,333

 

Marketable securities

 

 

37,404

 

 

 

30,800

 

Accounts and unbilled receivables, net

 

 

31,676

 

 

 

38,446

 

Prepaid and other current assets

 

 

19,079

 

 

 

20,631

 

Total current assets

 

 

145,648

 

 

 

130,210

 

 

 

 

 

 

 

 

 

 

Capitalized software development, net

 

 

42,472

 

 

 

40,643

 

Property and equipment, net

 

 

11,086

 

 

 

13,005

 

Operating lease right of use assets, net

 

 

18,172

 

 

 

20,114

 

Goodwill and intangible assets, net

 

 

249,108

 

 

 

259,410

 

Deferred commissions

 

 

31,777

 

 

 

31,700

 

Other assets

 

 

4,568

 

 

 

4,860

 

Total assets

 

$

502,831

 

 

$

499,942

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable, accrued, and other liabilities

 

$

27,633

 

 

$

34,738

 

Deferred revenue

 

 

82,939

 

 

 

83,623

 

Total current liabilities

 

 

110,572

 

 

 

118,361

 

Deferred tax liabilities

 

 

15,177

 

 

 

16,132

 

Deferred revenue, noncurrent

 

 

1,671

 

 

 

2,169

 

Operating lease liability, noncurrent

 

 

17,944

 

 

 

20,247

 

Other long-term liabilities

 

 

1,986

 

 

 

2,281

 

Total liabilities

 

 

147,350

 

 

 

159,190

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

Common stock

 

 

251,428

 

 

 

249,075

 

Accumulated other comprehensive loss

 

 

(884

)

 

 

(691

)

Retained earnings

 

 

104,937

 

 

 

92,368

 

Total shareholders’ equity

 

 

355,481

 

 

 

340,752

 

Total liabilities and shareholders' equity

 

$

502,831

 

 

$

499,942

 

 

HEALTHSTREAM, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2024

 

 

2023

 

Operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

15,118

 

 

$

10,623

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

30,779

 

 

 

30,550

 

Stock-based compensation

 

 

3,285

 

 

 

3,076

 

Amortization of deferred commissions

 

 

9,060

 

 

 

8,467

 

Deferred income taxes

 

 

(960

)

 

 

(2,634

)

Provision for credit losses

 

 

2,027

 

 

 

675

 

Loss on equity method investments

 

 

150

 

 

 

330

 

Change in fair value of non-marketable equity investments

 

 

—

 

 

 

(45

)

Other

 

 

(1,205

)

 

 

(603

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts and unbilled receivables

 

 

4,744

 

 

 

7,230

 

Prepaid and other assets

 

 

(8,210

)

 

 

(11,748

)

Accounts payable, accrued, and other liabilities

 

 

(7,105

)

 

 

683

 

Deferred revenue

 

 

(1,183

)

 

 

3,554

 

Net cash provided by operating activities

 

 

46,500

 

 

 

50,158

 

 

 

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

 

 

 

Business combinations, net of cash acquired

 

 

—

 

 

 

(6,621

)

Changes in marketable securities

 

 

(5,361

)

 

 

(19,235

)

Proceeds from sale of non-marketable equity investments

 

 

765

 

 

 

45

 

Purchases of property and equipment

 

 

(1,198

)

 

 

(1,854

)

Payments associated with capitalized software development

 

 

(20,107

)

 

 

(19,552

)

Net cash used in investing activities

 

 

(25,901

)

 

 

(47,217

)

 

 

 

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

 

 

 

Taxes paid related to net settlement of equity awards

 

 

(932

)

 

 

(817

)

Repurchases of common stock

 

 

—

 

 

 

(1,648

)

Payment of cash dividends

 

 

(2,551

)

 

 

(2,301

)

Net cash used in financing activities

 

 

(3,483

)

 

 

(4,766

)

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

40

 

 

 

(75

)

Net increase (decrease) in cash and cash equivalents

 

 

17,156

 

 

 

(1,900

)

Cash and cash equivalents at beginning of period

 

 

40,333

 

 

 

46,023

 

Cash and cash equivalents at end of period

 

$

57,489

 

 

$

44,123

 

 

Reconciliation of GAAP to Non-GAAP Financial Measures(1)

Operating Results Summary

(In thousands)

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

GAAP net income

 

$

5,725

 

 

$

3,867

 

 

$

15,118

 

 

$

10,623

 

Deferred revenue write-down

 

 

—

 

 

 

30

 

 

 

-

 

 

 

128

 

Interest income

 

 

(1,007

)

 

 

(667

)

 

 

(2,856

)

 

 

(1,580

)

Interest expense

 

 

26

 

 

 

33

 

 

 

75

 

 

 

99

 

Income tax provision

 

 

1,754

 

 

 

1,586

 

 

 

4,202

 

 

 

2,471

 

Stock-based compensation expense

 

 

1,131

 

 

 

1,038

 

 

 

3,285

 

 

 

3,076

 

Depreciation and amortization

 

 

10,073

 

 

 

10,403

 

 

 

30,779

 

 

 

30,550

 

Change in fair value of non-marketable equity investments

 

 

—

 

 

 

(45

)

 

 

—

 

 

 

(45

)

Adjusted EBITDA

 

$

17,702

 

 

$

16,245

 

 

$

50,603

 

 

$

45,322

 

(1) This press release presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing its financial results and ongoing operational performance.

 

Reconciliation of GAAP to Non-GAAP Financial Measures

Financial Outlook for 2024

(In thousands)

(Unaudited)

 

 

 

Low

 

 

High

 

Net income

 

$

18,500

 

 

$

19,500

 

Interest income

 

 

(3,700

)

 

 

(3,800

)

Interest expense

 

 

100

 

 

 

100

 

Income tax provision

 

 

5,400

 

 

 

5,700

 

Stock-based compensation expense

 

 

4,400

 

 

 

4,500

 

Depreciation and amortization

 

 

41,300

 

 

 

41,500

 

Adjusted EBITDA

 

$

66,000

 

 

$

67,500

 

This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2024 and our quarterly dividend policy, that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including as a result of negativeeconomic conditions, inflationary conditions, geopolitical instability (including as the result of the Russia/Ukraine conflict, the conflict in the Middle East, and the potential expansion of such conflicts), legal requirements and contractual restrictions which may affect continuation of our quarterly cash dividend policy and the declaration and/or payment of dividends thereunder, which may be modified, suspended, or canceled in any manner and at any time that our Board may deem necessary or appropriate,as well as risks referenced in the Company’s Annual Report on Form 10-K for the year ended December 31,2023, filed on February 26, 2024, and in the Company’s other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.

Scott A. Roberts
Chief Financial Officer
(615) 301-3182
ir@healthstream.com

Media:
Mollie Condra, Ph.D.
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com

Source: HealthStream, Inc.